221 filings
Page 9 of 12
CORRESP
aguk226gq ftm4df1
22 Jan 18
Correspondence with SEC
12:00am
CORRESP
rfsb0
22 Jan 18
Correspondence with SEC
12:00am
CORRESP
xgf9b3mrex9mi
22 Jan 18
Correspondence with SEC
12:00am
8-K
nh0w72b
18 Jan 18
Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol
12:00am
UPLOAD
9g8t6gjci0movvfpop
17 Jan 18
Letter from SEC
12:00am
CT ORDER
aiv2ucou3fnbs3fw
12 Jan 18
Confidential treatment order
12:00am
DRS
o4ldp3tutnio69ymj
5 Jan 18
Draft registration statement
12:00am
8-K
toenedp0jdrt
5 Jan 18
Entry into a Material Definitive Agreement
12:00am
8-K
8ee2p5jnklw2 qyu4kt
29 Dec 17
Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel
12:00am
8-K
q4h919q wt
15 Dec 17
Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis
12:00am
8-K
f5ga0c4ehm49ebn
1 Dec 17
Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle
12:00am
8-K
w2779 4puqycuo6rrhrq
9 Nov 17
Athenex, Inc. Announces Third Quarter 2017 Results
12:00am
8-K
vdb1 pmqr7fjc
5 Oct 17
Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program
12:00am
8-K
zfjdpktyd9smerxa8jc
5 Oct 17
Unregistered Sales of Equity Securities
12:00am
8-K
f0uwm
8 Sep 17
Entry into a Material Definitive Agreement
12:00am
10-Q
2wqcmm
14 Aug 17
Quarterly report
12:00am
8-K
cm5y2apgl122rbez
14 Aug 17
Athenex, Inc. Announces Second Quarter 2017 Results
12:00am
8-K
ifo6uwj1 st7t0t
5 Jul 17
Athenex, Inc. Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA
12:00am